- already enrolled in another clinical trial evaluating antiviral or immunobiological therapy for the treatment of covid-19. - iga deficiency - presence of a clinical condition that does not allow infusion of 400 ml of volume at clinical discretion - pregnancy or breastfeeding - receipt of immunoglobulin in the last 30 days - presence of significant risk of death within the next 48 hours at clinical discretion.

- already enrolled in another clinical trial evaluating antiviral or immunobiological therapy for the treatment of covid-19. - iga deficiency - presence of a clinical condition that does not allow infusion of 400 ml of volume at clinical discretion - pregnancy or breastfeeding - receipt of immunoglobulin in the last 30 days - presence of significant risk of death within the next 48 hours at clinical discretion.